These therapeutic effects were associated with increased CD4+ and CD8+ T cells, and IFN-γ and TNF-α in tumor tissues, indicating that CMFn@OXA NPs induced a strong anti-tumor immune response. The gene discussed is CD8A; the disease is neoplasm.